What is Bit Bio?
Bit Bio operates at the critical intersection of synthetic biology and regenerative medicine. By leveraging its patented opti-ox gene-targeting platform, the company enables the precise, inducible expression of transcription factors to reprogram human induced pluripotent stem cells (iPSCs) into highly defined, mature cell types. This capability addresses a significant bottleneck in modern biomedical research, providing researchers and pharmaceutical developers with consistent, scalable human cell models. As the industry shifts toward more personalized and effective therapeutic interventions, Bit Bio's platform serves as a foundational infrastructure for the next generation of drug discovery and cell-based treatments, positioning the company as a vital partner in the global life sciences ecosystem.
How much funding has Bit Bio raised?
Bit Bio has raised a total of $255M across 6 funding rounds:
Angel/Seed
$471K
Series A
$41.5M
Series B
$103M
Other Financing Round
$30M
Private Equity
$30M
Series C
$50M
Angel/Seed (2017): $471K with participation from Jonathan Milner
Series A (2020): $41.5M led by Richard Klausner, Blueyard Capital, Arch Venture Partners, and Foresite Capital
Series B (2021): $103M supported by Arch Ventures, National Resilience, Foresite Capital, and Charles River Laboratories
Other Financing Round (2024): $30M featuring M&G Investments, Tencent, and ARCH Venture Partners
Private Equity (2024): $30M backed by BlueYard Capital, Puhua Capital, M&G, and ARCH Venture Partners
Series C (2026): $50M with participation from M&G
Key Investors in Bit Bio
ARCH Venture Partners
A leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists to commercialize innovations.
Foresite Capital
A multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data to address significant unmet needs.
M&G
An international asset manager headquartered in London, providing institutional and individual investors with diversified exposure to high-growth sectors including biotechnology.
What's next for Bit Bio?
With this latest infusion of capital, Bit Bio is well-positioned to accelerate its commercial scaling and deepen its research pipeline. The company's strategic trajectory suggests a focus on expanding its library of mature cell types and enhancing its manufacturing capabilities to meet the growing demand for high-fidelity human cell models. By maintaining a robust balance sheet, Bit Bio is prepared to navigate the complexities of clinical translation, potentially moving its proprietary cell therapies closer to human trials. The ongoing support from institutional backers indicates a long-term commitment to the company's vision of standardizing human cell production, which will likely remain a core pillar of its growth strategy in the coming fiscal periods.
See full Bit Bio company page
